Extension study of XTMAB-16 for pulmonary sarcoidosis
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing clinical trials.
This study is an extension of a previous trial for the drug XTMAB-16 in people with pulmonary sarcoidosis. It allows patients who completed the earlier study to continue receiving the treatment and be monitored for safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the main XTMAB-16 study (XTMAB-16-201) up to Week 12 or Week 24
- You must be on a stable dose of steroids for at least 2 weeks before starting this extension study
- You cannot have had serious side effects that caused you to stop treatment in the previous study
- The treatment must have worked or been stable in the previous study
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, XTMAB-16, for people with pulmonary sarcoidosis (lung inflammation) that may also affect other parts of the body. The study first checks how the body handles different doses, then looks for signs of improvement.
This early-phase study tests XTMAB-16 to improve lung sarcoidosis in people who still have symptoms despite standard steroid-type treatment. It may help reduce inflammation and improve breathing, while also learning the safest dose and how the treatment works in humans.
This study tests a new medication, OATD-01, for people with active sarcoidosis in their lungs. It aims to see how safe and effective the drug is and if it can improve symptoms.
This trial tests if a steroid combination medicine called Compound Betamethasone works well for people recently diagnosed with pulmonary sarcoidosis who haven't yet had treatment. The goal is to see if it can control the disease with fewer side effects than usual steroids.
This trial studies a treatment approach for people with active cardiac sarcoidosis, confirmed by specific heart rhythm/heart function problems and a PET scan. It may help by targeting the active inflammation driving heart conduction problems, rhythm events, or weak heart pumping.
This study follows adults with sarcoidosis to see which body “risk signals” (biomarkers) can predict whether the disease will get better or worse. It may help doctors monitor sarcoidosis more closely and choose the right treatment sooner.
Hear when a new Pulmonary Sarcoidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.